| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |
| MRSA | 2 (9.52%)* | 1 (10%) | 4 (22%) | 2 (5.51%) | 1 (4.5%) | 3 (20%) |
| Enterocc Vanco-R | 0 | 0 | 0 | 0 | 0 | 0 |
| MDR-Pseudom.A | 3 (14%) | 1 (10% | 3 (16%) | 4 (11%) | 3 (13%) | 1 (6.6%) |
| Acinetob. Imipenem-R | 13 (62%) | 6 (60%) | 9 (50%) | 18 (50%) | 7 (31%) | 3 (20%) |
| Enterobact.(ESBL) | 3 (14%) | 2 (20%) | 2 (11%) | 12 (33%) | 11 (50%) | 7 (46%) |
| Carbapenem-R GN | 0 | 0 | 0 | 0 | 0 | 1 (6.61%) |
| Total | 21 | 10 | 18 | 36 | 22 | 15 |
| (* Percentages referring to the total of the different microorganisms responsible for MDR infections). | ||||||